| abstract |
The present invention relates to a peptide which specifically binds only to neuropilin 1 (NRP1) without binding to neuropilin 2 (NRP2), a fusion protein, a small molecule drug, a nanoparticle or a liposome , A pharmaceutical composition for treating or preventing cancer or a neovascularization-related epidemic thereof, and a diagnostic composition. In addition, the present invention also provides a polynucleotide encoding a peptide specifically binding to NRP1. Further, the present invention relates to a method for screening a peptide specifically binding to NRP1. The antibody heavy chain constant region fused with a peptide specifically binding to NRP1 according to the present invention has a property of specifically binding to NRP1, and is selectively accumulated in tumor tissue when administered in vivo, and the cells of tumor vascular endothelial cells The gap is widened to enhance the extravasation and the penetration into the tumor tissue increases. In addition, the antibody heavy chain constant region fused with a peptide specifically binding to NRP1 according to the present invention inhibits the binding of angiogenic factor (VEGF) to neuropilin 1, and thus has an ability to inhibit angiogenesis in tumor tissue. Thus, the antibody heavy chain constant region fused with a peptide according to the present invention exhibits in vivo tumor suppressor activity. |